Search the Video Library

Filter by Date

Video Language

Filter by Cancer Type:

Displaying Results 136 - 139 of 139

SBRT for Oligometastatic Lung Cancer

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Immunotherapy for First Line Therapy of Advanced NSCLC

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

What is the Optimal Duration of Immunotherapy?

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Spanish Blood Cancer Library - What are the risks and benefits of Ibrutinib and Idelalisib? How do you manage the side effects of the new kinase inhibitors?
¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?

GRACE sat down with Dr. Marco Ruiz to discuss "What are the risks and benefits of Ibrutinib and Idelalisib?" for our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments.